0001157523-19-002257.txt : 20191113 0001157523-19-002257.hdr.sgml : 20191113 20191113070036 ACCESSION NUMBER: 0001157523-19-002257 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20191113 FILED AS OF DATE: 20191113 DATE AS OF CHANGE: 20191113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BELLUS Health Inc. CENTRAL INDEX KEY: 0001259942 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39034 FILM NUMBER: 191211658 BUSINESS ADDRESS: STREET 1: 275 ARMAND-FRAPPIER BLVD. CITY: LAVAL STATE: A8 ZIP: H7V 4A7 BUSINESS PHONE: 450-680-4500 MAIL ADDRESS: STREET 1: 275 ARMAND-FRAPPIER BLVD. CITY: LAVAL STATE: A8 ZIP: H7V 4A7 FORMER COMPANY: FORMER CONFORMED NAME: NEUROCHEM INC DATE OF NAME CHANGE: 20030814 6-K 1 a52128017.htm BELLUS HEALTH INC. 6-K
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
  
 
FORM 6-K
 
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the month of November 2019
 
 
Commission File Number:  001-39034
 
 
BELLUS HEALTH INC.
 (Name of registrant)
275 Armand-Frappier Blvd.
 Laval, Québec
 H7V 4A7
Canada
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 
☐    Form 20-F
☒    Form 40-F

 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
BELLUS Health Inc.
 
 
 
 
 
 
 
 
 
 
 
Date: November 13, 2019
By:
/s/ François Desjardins
 
 
 
Name:   François Desjardins
 
 
 
Title:     Vice President, Finance
Form 6-K Exhibit Index
 
Exhibit Number
  
Document Description
 
 
 
 

EX-99.1 2 a52128017ex99_1.htm EXHIBIT 99.1
Exhibit 99.1
BELLUS Health Inc.
275 Armand-Frappier Blvd.
Laval, Quebec, Canada H7V 4A7

BELLUS Health to Present at Jefferies Global Healthcare Conference in London

LAVAL, Quebec, November 13, 2019 – BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company on Wednesday, November 20, 2019 at the Jefferies Global Healthcare Conference in London.
 
Presentation Details:
 
Event: Jefferies Global Healthcare Conference in London
Date/Time: Wednesday, November 20, 2019 at 9:20 a.m. GMT
Location: London
 
A live webcast may be accessed on the Events and Presentations page under the Investors & News section of BELLUS Health's website at www.bellushealth.com. Following the event, an archived webcast and presentation will be available on the Company’s website.
 
About BELLUS Health
 
BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company’s product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.
 
FOR MORE INFORMATION, PLEASE CONTACT:
 
Investors:
François Desjardins
Vice President, Finance
450-680-4525
fdesjardins@bellushealth.com

Solebury Trout
Chad Rubin
646-378-2947
crubin@troutgroup.com

Media:
Solebury Trout
Joshua R. Mansbach
646-378-2964
jmansbach@troutgroup.com
 
SOURCE: BELLUS Health Inc.
 GRAPHIC 3 bellus_logo.jpg LOGO begin 644 bellus_logo.jpg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end